Disease · MONDO_0016367

dermatomyositis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. dermatomyositis. Diseases, record MONDO_0016367. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0016367

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: dermatomyositis; Open Targets
Open Targets ID: MONDO_0016367; Open Targets
Other names: Adult Type Dermatomyositides, Adult Type Dermatomyositis, DM, DM - Dermatomyositis, Dermatomyositides, Dermatomyositides, Adult Type, Dermatomyositis (disorder), Dermatomyositis, Adult Type, Dermatomyositis, Childhood Type, Dermatopolymyositides, Dermatopolymyositis, unspecified, Dermatopolymyositis, unspecified (disorder), Polydermatomyositis, Polymyositis Dermatomyositis, Polymyositis with skin involvement, Polymyositis-Dermatomyositides, Wagner-Unverricht syndrome, [X]Dermatopolymyositis, unspecified, [X]Dermatopolymyositis, unspecified (disorder), dermatopolymyositis; Open Targets
Disease Ontology: DOID:10223; Disease Ontology
MeSH: D003882; MeSH
NCI Thesaurus: C26744; NCI Thesaurus
Orphanet: ORPHA:221; Orphanet
Highest stage of its drugs: Approval, for 3 of its 48 drugs, from DailyMed; Open Targets

Drugs48

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
PREDNISONE	CHEMBL635	Small molecule	Approval	DailyMed	3	2	2	Drugs and targets
PREDNISOLONE	CHEMBL131	Small molecule	Approval	DailyMed	2	1	1	Drugs and targets
CORTISONE ACETATE	CHEMBL1650	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
DAZUKIBART	CHEMBL4297808	Antibody	Phase 3	ClinicalTrials.gov	5	4	4	Drugs and targets
HUMAN IMMUNOGLOBULIN G	CHEMBL1201599		Phase 3	ClinicalTrials.gov	4	4	1	Drugs and targets
ALDESLEUKIN	CHEMBL1201438	Protein	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
BARICITINIB	CHEMBL2105759	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
BREPOCITINIB	CHEMBL4297477	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
LENABASUM	CHEMBL456341	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
ANIFROLUMAB	CHEMBL2364653	Antibody	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 48

See all 48 drugs

Targets56

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
JAK1	Janus Kinase (JAK)	4	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK1 inhibitor	Phase 3	https://conductscience.org/library/genes/3716	Drugs and targets
TYK2	Janus Kinase (JAK)	4	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase TYK2 inhibitor; Tyrosine-protein kinase TYK2 negative allosteric modulator	Phase 3	https://conductscience.org/library/genes/7297	Drugs and targets
JAK2	Janus Kinase (JAK)	3	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK2 inhibitor	Phase 3	https://conductscience.org/library/genes/3717	Drugs and targets
NR3C1	Glucocorticoid receptor	3	Glucocorticoid receptor agonist	Approval	https://conductscience.org/library/genes/2908	Drugs and targets
C5	Complement C5	2	Complement C5 inhibitor	Phase 2/3	https://conductscience.org/library/genes/727	Drugs and targets
JAK3	Janus Kinase (JAK)	2	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK3 inhibitor	Phase 2	https://conductscience.org/library/genes/3718	Drugs and targets
TLR7	Toll-like receptor 7	2	Toll-like receptor 7 antagonist	Phase 2	https://conductscience.org/library/genes/51284	Drugs and targets
TLR8	Toll-like receptor 8	2	Toll-like receptor 8 antagonist	Phase 2	https://conductscience.org/library/genes/51311	Drugs and targets
TNF	Tumor necrosis factor	2	TNF-alpha inhibitor	Phase 2/3	https://conductscience.org/library/genes/7124	Drugs and targets
CD6	T-cell differentiation antigen CD6	1	T-cell differentiation antigen CD6 inhibitor	Phase 1	https://conductscience.org/library/genes/923	Drugs and targets

1 to 10 of 56

See all 56 targets

Trials62

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 6 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00106184	Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM)	Phase 2	200	2015-03-04	Myositis, Dermatomyositis, Polymyositis, Juvenile Dermatomyositis	RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT00979654	A Study to Evaluate the Long-Term Safety of MEDI-545 in Adult Participants With Systemic Lupus Erythematosus or Myositis	Phase 2	118	2016-08-23	Systemic Lupus Erythematosus	SIFALIMUMAB	Its record names the disease	ClinicalTrials.gov
NCT02728752	Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy)	Phase 3	95	2021-04-21	Dermatomyositis	HUMAN IMMUNOGLOBULIN G	Its record names the disease	ClinicalTrials.gov
NCT03181893	A Study In Adults With Moderate To Severe Dermatomyositis	Phase 2	75	2023-09-14	Dermatomyositis	DAZUKIBART	Its record names the disease	ClinicalTrials.gov
NCT03981744	A Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care Treatments	Phase 3	51	2024-05-13	Polymyositis, Dermatomyositis	USTEKINUMAB	Its record names the disease	ClinicalTrials.gov
NCT04999020	Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis	Phase 2/3	38	2024-12-06	Dermatomyositis	RAVULIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT02043548	Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis	Phase 2	36	2020-10-30	Dermatomyositis, Polymyositis	TOCILIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00651040	Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With PM and DM	Phase 3	31	2016-05-12	Polymyositis, Dermatomyositis	METHOTREXATE, PREDNISONE	Its record names the disease	ClinicalTrials.gov
NCT02612857	Trial of IMO-8400 in Adult Patients With Dermatomyositis	Phase 2	30	2019-10-10	Dermatomyositis	BAZLITORAN	Its record names the disease	ClinicalTrials.gov
NCT00504348	Investigation in Myositis-associated Pneumonitis of Prednisolone And Concomitant Tacrolimus	Phase 2/3	25	2020-03-24	Interstitial Pneumonitis, Polymyositis, Dermatomyositis	PREDNISOLONE, TACROLIMUS	Its record names the disease	ClinicalTrials.gov

1 to 10 of 62

See all 62 trials

Comparisons in its trials45

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Treatment Group A (Rituximab Wks 0 and 1) vs Treatment Group B (Rituximab Wks 8 and 9): Response Rates (Proportion of Improved Patients) Between Groups A (Rituximab Wks 0 and 1) and B (Rituximab Wks 8 and 9) at Week 8	14 of 96	21 of 104	200	NCT00106184	Trial comparisons
Treatment Group A (Rituximab Wks 0 and 1) vs Treatment Group B (Rituximab Wks 8 and 9): 20% Improvement in Manual Muscle Testing (MMT) Over Baseline on Two Consecutive Time Points (Muscle is the Primary Organ of Involvement, and MMT is the One Objective Measurement of the Definition of Improvement [DOI])	14 of 96	21 of 104	200	NCT00106184	Trial comparisons
Treatment Group A vs Treatment Group B: serious adverse events	24 of 96	41 of 104	200	NCT00106184	Trial comparisons
Overall Period Octagam vs First Period Placebo: deaths from any cause	0 of 95	0 of 48	143	NCT02728752	Trial comparisons
Overall Period Octagam vs First Period Placebo: serious adverse events	14 of 95	2 of 48	143	NCT02728752	Trial comparisons
Octagam10% vs Placebo: Measure the Number of Patients Who Had an Increase of ≥20 Points on the Total Improvement Score (TIS)	37 of 47	21 of 48	95	NCT02728752	Trial comparisons
RCP: Ravulizumab vs RCP: Placebo: Number of Participants With CDASI Response (>=7-point Improvement) at Week 26	6 of 26	4 of 12	38	NCT04999020	Trial comparisons
RCP: Ravulizumab vs RCP: Placebo: Number of Participants With Clinical Worsening (CW) During the RCP At 2 Consecutive Visits	2 of 26	0 of 12	38	NCT04999020	Trial comparisons
RCP: Ravulizumab vs RCP: Placebo: Number of Participants With ≥ 20-Point Improvement Response on IMACS-TIS (TIS20) Response at Week 26	14 of 26	9 of 12	38	NCT04999020	Trial comparisons
RCP: Ravulizumab vs RCP: Placebo: Number of Participants With Response Related to Muscle Enzymes: Normalization of Most Abnormal Baseline Enzyme at Week 26	4 of 26	1 of 12	38	NCT04999020	Trial comparisons

1 to 10 of 45

See all 45 comparisons in its trials

Papers from its trials35

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
31539061	RESULT	1	PubMed
23124935	RESULT	1	PubMed
22227955	RESULT	1	PubMed
15942915	RESULT	1	PubMed
327194	RESULT	1	PubMed
42646746	DERIVED	1	PubMed
42542380	DERIVED	2	PubMed
42273013	DERIVED	1	PubMed
41910335	DERIVED	1	PubMed
41874840	DERIVED	1	PubMed

1 to 10 of 35

See all 35 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0016367

GET https://conductscience.org/api/diseases/v1/MONDO_0016367/drugs?page=2

API reference For AI assistants